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Myelodysplastic syndromes (MDSs) are clonal disorders of hematopoiesis that exhibit 
heterogeneous clinical presentation and morphological findings, which complicates 
diagnosis, especially in early stages. Recently, refined definitions and standards in the 
diagnosis and treatment of MDS were proposed, but numerous questions remain. 
Multiparameter flow cytometry (MFC) is a helpful tool for the diagnostic workup of 
patients with suspected MDS, and various scores using MFC data have been developed. 
However, none of these methods have achieved the sensitivity that is required for a 
reassuring diagnosis in the absence of morphological abnormalities. One reason may be 
that each score evaluates one or two lineages without offering a broad view of the dys-
plastic process. The combination of two scores (e.g., Ogata and Red Score) improved 
the sensitivity from 50–60 to 88%, but the positive (PPV) and negative predictive values 
(NPV) must be improved. There are prominent differences between study groups when 
these scores are tested. Further research is needed to maximize the sensitivity of flow 
cytometric analysis in MDS. This review focuses on the application of flow cytometry for 
MDS diagnosis and discusses the advantages and limitations of different approaches.
Keywords: myelodysplastic syndromes, phenotypic aberrancies related to dysplasia, myeloid maturation patterns, 
FCSS scores, prognostic value of immunophenotypic scores
iNTRODUCTiON
The diagnosis and prognosis of myelodysplastic syndromes (MDS) relies on cytology and cytoge-
netic data, but recent progress in Multiparameter flow cytometry (MFC) improved the sensitiv-
ity required to obtain a reassuring MDS diagnosis in the absence of prominent morphological 
abnormalities. An important drawback of the immunophenotypic method in MDS is related to the 
absence of the antigen imprints associated with dysplasia. The most commonly used method is the 
pattern recognition-based approach. However, flow cytometry in MDS immunophenotyping has 
progressed over the last several years with the development of 4- to 10-color multi-laser cytom-
eters, the development of monoclonal antibodies directed toward an increased number of antigens 
on hematopoietic cells, the discovery of new fluorochromes, and the development of innovative 
software for flow cytometry data analysis. The new analysis programs allow better discrimination 
of the cell populations using the Automatic Population Separator (APS), which provides the largest 
view of cell antigenic expression using a backbone-based analysis strategy (i.e., the Calculate Data 
tool from Cytognos Infinicyt™ Flow Cytometry Software, Salamanca, Spain) or the construction 
of databases, which provide a better understanding of the normal maturation pathways of bone 
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marrow (BM) cells and offer a tool to interpret the different 
maturation abnormalities in a non-subjective manner.
Data in the field of MDS immunophenotyping remain scarce 
and contradictory despite this progress, primarily due to the lack 
of standardization in antibody combination panels, cytometer 
settings, and analysis strategies.
This review focuses on the application of flow cytometry for 
MDS diagnosis and discusses the advantages and limitations of 
different approaches.
MFC ANALYSiS iN MDS
Multiparameter flow cytometry is increasingly used to reinforce 
MDS diagnosis (particularly for reassuring the diagnosis of the 
low-grade MDS and “MDS unclassifiable” categories), deter-
mine the prognostic outcome, and monitor the evolution of 
MDS patients during therapeutic interventions. The presence 
of three or more phenotypic abnormalities involving one or 
more of the myeloid lineages may be considered “suggestive” of 
MDS, but flow cytometric abnormalities alone in the absence of 
conclusive morphological and/or cytogenetic features are not 
diagnostic of MDS (1).
Multiparameter flow cytometry assesses dysplastic changes 
in maturing myeloid cell compartments (e.g., neutrophil, mono-
cytic and erythroid lineages) and evaluates immature progenitor 
compartments (e.g., myeloid and B lymphoid lineages).
Several phenotypic aberrancies related to dysplasia were 
described for this purpose and included in different scoring 
systems. The analytic strategies are based on interpretations 
of surface marker abnormalities (e.g., increased or decreased 
fluorescence intensity of antigens compared to normal BM 
counterparts, asynchronous expression of antigens, or lineage-
aberrant expression). Several quantitative differences in imma-
ture progenitor compartments versus normal counterparts were 
also noted (e.g., increased percentages of myeloid progenitors and 
diminished percentages of B lymphoid progenitors).
Analysis of immature Progenitor 
Compartments
Blast quantification is essential for MDS and acute myeloid 
leukemia (AML) because the blast count contributes to the 
WHO classification of MDS/AML and is part of all prognostic 
scoring systems (2, 3). Generally, a good correlation is observed 
between MFC and morphologic evaluation, but sometimes dif-
ferences can occur, mainly in cases with higher blast counts in 
cytology (2). The differences can occur if the MFC samples are 
hemodiluted (2, 3).
Recently, to overcome this problem, bone marrow purity 
(BMP) assessment has been proposed. For example, the BM 
blast percentage obtained in MFC should be adjusted accord-
ing to the number of lymphocytes. The method has limitations 
at the extremes of hemodilution, where slight variations in 
the lymphocyte number result in significant changes in BMP 
percentage. The cut-off of the BMP was set at 40%; below this 
value, the MFC analysis significantly underestimates the blast 
count (3).
The “Ogata score” was the first score developed as a screening 
test, primarily for the evaluation of immature progenitor com-
partments (4).
This score includes four parameters: the percentage of CD34+ 
myeloid progenitor cells in the BM, the frequency of B-cell 
precursors within the CD34+ compartment, CD45 expression on 
myeloid progenitors relative to CD45 expression on lymphocytes, 
and the evaluation of neutrophil granularity by comparison to 
SSC on lymphocytes. This score was tested in a prospective valida-
tion study comprising 134 low-grade MDS and 106 control BMs 
enrolled in two centers from Japan and Italy. The diagnostic sensi-
tivities were 65 and 89% and the specificities were 98 and 90% for 
a score ≥2 for the Japanese and Italian cohorts, respectively. Three 
other parameters (expression of CD11b, CD15, and CD56) were 
analyzed on CD34+ myeloblasts, but the results demonstrated 
that these parameters did not improve the diagnostic power (5).
However, the “Ogata score” has limited applicability in 
hypocellular BM samples and samples from pediatric patients (6).
A recent French multicenter study confirmed the feasibility of 
the Ogata score for MDS diagnosis, but highlighted its limitations 
in low-risk MDS (7).
The aberrant expression of lymphoid markers on CD34+ 
myeloblasts was observed in small numbers of MDS cases. The 
presence of CD5 was found in only 1.8% of MDS patients in an 
MLL Munich Leukemia Laboratory study (8) and 1.6% of MDS 
cases enrolled in a French multicenter study (7). The presence of 
CD7 on myeloid progenitors was observed in 3.5% (Kern study) 
and 9% of MDS BM samples in a French study (7).
These studies confirm previous Ogata data and reflect no 
need to include evaluation of CD5, CD11b, or CD15 and little 
need to include CD56 and CD7 expression in myeloid progenitor 
compartments in the performing MDS diagnosis.
The fact that the overestimation of CD5, CD7, and CD56 
expression may be due to inappropriate comparisons with the 
background of the blasts was highlighted (9), and this comparison 
may underlie the reason for the percentage discrepancy between 
the Ogata and French multicenter studies.
Kussick and coworkers performed a diligent study of more than 
800 samples and found that antigens were expressed abnormally 
by 50% or more of the cases in the MDS patient group, including 
HLA-DR, CD13, CD33, CD38, and CD117 (10).
There is a well-known physiological age-related variation in the 
precursor B-cell compartment composition (11). This variation is 
more evident in very young children below the age of 2 years (12).
In conclusion, the convenient interpretation of immunophe-
notyping results performed for evaluation of the B-cell precursor 
compartment requires the use of adequate reference data.
A diminution of B-lymphoid precursors was also observed 
in many primary immune deficiencies associated with agam-
maglobulinemia (12).
Analysis of Mature Neutrophils
The “Ogata score” also includes a criterion for neutrophil lineage 
evaluation, the morphometric parameter granularity, which is 
evaluated as a ratio between the side scatter (SSC) of granulocytes 
and the SSC of lymphocytes (the threshold for normal samples 
was set at 6). The specificity of the granulocyte/lymphocyte 
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(Gra/Ly) SSC ratio was reported at 89% (7), but discordance 
with the cytology evaluation was also reported (13). Two pos-
sible situations cause these differences: the increased proportion 
of mature circulating neutrophils due to BM hemodilution, 
which affects the Gra/Ly SSC ratio (14), and the presence of less 
than 10% dysplastic granulocytes (13). Flow cytometry seems 
more informative than cytology in the latter case (i.e., refractory 
anemia with or without ring sideroblasts, in which dysgranu-
lopoiesis may not exceed 10% of granulocytes according to the 
WHO recommendations) (13).
The Gra/Ly SSC peak channel ratio improved reproducibility, 
and it was the most useful for discriminating the differences in 
hypogranularity between MDS patients and other pathological 
conditions (14).
Numerous aberrant phenotypes are related to neutrophil 
dysplastic changes.
Kern et  al. developed a screening score that includes five 
MDS-typical aberrant antigen expression levels in the neutrophil 
compartment: abnormal expression of CD13/CD16 and CD11b/
CD16, aberrant expression of CD56, and lack of CD33 and CD64 
expression (15).
Figure 1 shows examples of the interpretation of flow cytomet-
ric profiles of the mature neutrophil compartment with respect to 
the analysis of dysplasia as described by Kern and collaborators.
Dyssynchronous expression of CD13/CD16 and CD11b/
CD16 was considered if the discordance detected, compared to 
the “normal” pattern, was at least a half-log of the signal intensity 
in at least one parameter (8, 13). Possible drawbacks in interpreta-
tions of the loss of CD16 are related to the inclusion of eosinophils 
in the neutrophil gate and the presence of apoptotic cells, which 
are also observed in two pathological non-MDS conditions, e.g., 
paroxystic nocturnal hemoglobinuria and patients with a genetic 
polymorphism (16).
Even the International/European LeukemiaNet (ELN) 
Working Group for Flow Cytometry in MDS considers the aber-
rant expression of CD56 on granulocytes as an MDS-associated 
feature, but the interpretation of this parameter may raise 
problems of misinterpretation (e.g., aberrant expression should 
be considered if the CD56 expression is superior to at least a 
1-log decade of signal intensity compared to normal controls) 
(9, 16). Increased CD56 expression is also found on activated 
granulocytes (9).
Relatively low-level CD56 expression on 10–25% of maturing 
granulocytes is observed in the setting of BM regeneration with 
or without granulocyte colony-stimulating factor therapy (17).
An absence of CD33 was rarely reported, and it may be related 
to a polymorphism. The altered expression of this marker in this 
case concerns all myeloid populations (e.g., myeloid progenitors, 
neutrophils, and monocytes) (9).
CD64 absence or diminution is variable, and this variation 
may be the reason that it was not included in the last ELN recom-
mendation (6).
The European LeukemiaNet Working Group proposed other 
parameter evaluations for phenotypic dysplastic changes on 
granulocytes, including the abnormal expression of CD36 and 
CD10 and an aberrant CD15/CD10 pattern (6). A possible 
upregulation of CD36 on the granulocyte surface may be related 
to cell apoptosis, and this marker is required for phagocytosis 
by macrophages and in the suppression of macrophage proin-
flammatory functions, consequently acting on the synthesis of 
proinflammatory cytokines, such as TNFα, IL-1β, and IL-6, as 
well as inducible nitric oxide synthase (iNOS) (18). Figure  2 
shows the abnormal expression of CD36 on mature granulo-
cytes (CD10+) in a case of refractory anemia with excess of 
blasts (RAEB).
Analysis of Mature Monocytes
The following most frequent phenotypic changes were observed 
on mature monocytes: decreased SSC; arrest of maturation 
(Figure 3A); diminution of CD45, CD11b, HLA-DR, and CD15 
expression; aberrant pattern of HLA-DR/CD11b; abnormal 
expression (higher or lower) of CD16 on CD11b+ monocytes; 
abnormal expression of CD36, CD56 (Figure  3B), and CD7; 
partial absence of CD13 or CD33 (Figure  3C); and abnormal 
pattern of CD36/CD14 (6).
Analysis of the erythroid Compartment
The European LeukemiaNet Working Group describes four 
major abnormalities: the increased percentage of immature 
CD117+ erythroid precursors, the abnormal heterogeneous and 
low expression of CD36 and CD71, and an aberrant pattern of 
CD71/CD235 expression (6).
A useful tool for the evaluation of erythroid lineage is the 
Red score, developed by Mathis et al. (20). This score takes into 
account the following three parameters: the coefficient of vari-
ance of CD36 and CD71 on CD36+ CD64− CD71+ erythroblasts 
and the hemoglobin value. A score of ≥3 is very useful to detect 
the dysplastic changes observed on erythroid lineages, with a 
sensibility of 77.5%, specificity of 90%, positive predictive values 
(PPV) of 97%, and negative predictive value (NPV) of 49% (20). 
The authors affirm that a major drawback of the evaluation of 
dysplastic changes in the erythroid lineage using cytometry is 
red cell lysis during sample preparation. A possible improvement 
could be obtained using a nuclear dye (e.g., CyTRAK orange, 
DRAQ5, or DRAQ7) that allows the discrimination of nucleated 
and non-nucleated cells in MCF (20).
However, a recent study shows that the lysis method has the 
most consistent quantitative antigen intensities (21).
The CV evaluation of CD36 and CD71 on CD36+ CD64− CD71+ 
erythroblasts has been proposed as most useful for evaluations of 
dysplastic changes in erythroid lineages (20, 21). Other markers 
can also be informative for dysplastic changes in the erythroid 
lineage, such as CD235a (20–26) and CD105 (21).
A recent study conducted to expand the understanding 
of immunophenotypic analysis of erythropoiesis and further 
evaluated the dysplastic changes of the erythroid lineage in MDS 
included the following characteristics: the intensity of expression 
of CD71, CD36, CD105, CD235a, and CD117; the frequency 
of CD105bright erythroid cells; and the proliferation index of the 
immature (CD105+) and mature (CD235a+, CD71+, and CD36+) 
erythroid cells. Changes in the CD36 and CD71 intensity 
were frequently observed in the MDS cohort, as were a loss of 
mature erythroid progenitors and an increased frequency of the 
CD105bright population.
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FiGURe 1 | eight-color flow cytometric analysis of the different cellular compartments in bone marrow (BM) aspirates with a focus on granulocytic 
lineage maturation. The first row shows a global overview of BM cellular compartments projected on SSC/CD45 graphs, including erythroblasts (orange), the 
CD45low progenitor/precursor compartment (light blue), monocytic lineage precursors (red), more mature monocytic cells (green), and lymphocytes (dark blue). Dot 
plot (C) shows the neutrophil and monocyte hypogranularity compared to two normal cases (A,B). The next three rows show the progression from CD117+ CD13+ 
CD16− neutrophil precursors (salmon color) through two intermediary stages of maturation from CD117− CD13−/+low CD16− (deep pink) and CD13−/+low CD16+var 
(crimson) to mature CD13+hi CD16+hi (fuchsia) neutrophils in one normal bone marrow (D) and two MDS cases (e,F). Note the differences in the maturation patterns 
evaluated on CD16/CD13, CD13/CD11b, and CD16/CD11b plots between the normal BM and MDS cases. The last row shows two types of aberrancies observed 
in granulocytes in MDS settings compared with normal BM: the absence of CD33 (H) compared to normal expression (G), and the aberrant expression of CD56 (J) 
expressed as a 1-log difference compared with normal granulocytes (i).
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The incorporation of other erythroid antigen aberrancies, 
such as that of CD105, into flow cytometry scores would allow 
the detection of low-grade MDS, but prospective studies are 
necessary (21).
A good correlation between the phenotypic abnormali-
ties of the BM erythroid compartment in MDS patients and 
the increased percentage of nucleated red blood cells in the 
circulation that is a good discriminator between regenerative 
and non-regenerative anemias, making this parameter a good 
choice for erythroid evaluation scores. The new parameters 
appear to be sensitive for the detection of small changes in 
the number of red cells with inadequate hemoglobinization 
CD45
SS
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CD10
C
D
13
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64
CD7
C
D
56
CD33
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D
36
FiGURe 2 | Representative case of refractory anemia with excess of blasts for which the parameters of the Kern scores are not informative, but the 
CD36 expression on mature CD10+ granulocytes is remarkable (last row, left side) compared to normal counterpart (last row, right side). The figure 
depicts the significant reduction of erythroblasts (gray), the proliferation of CD45+low blasts (yellow), and the aberrant expression of CD36 on CD10+ granulocytes. 
The aberrant expression of CD56 is not observed on monocytes (CD33+hi CD36+ CD64+ CD14+, green color) or granulocytes (CD13+var CD64+low CD33+ CD10− 
immature granulocytes, deep pink, and CD13+hi CD64+low CD33+int CD10+ mature granulocytes, fuchsia). The absence of CD33 expression on the granulocytes is 
not noted.
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(reticulocyte hemoglobin content – Ret He and the percentage 
of hypochromic red cells – % Hypo He, which reflect the iron 
status over the previous 2–3 months). They are also useful for 
the detection of the circulatory immature reticulocyte fraction 
(IRF), which has been found to be elevated in MDS settings 
(27, 28). These parameters, in addition to the automated reticu-
locyte count, can be used to identify qualitative abnormalities 
of erythropoiesis.
Potential Utility of Multiparameter 
Flow Cytometric Scoring Systems in 
Myelodysplastic Syndromes
Over time, several flow cytometric scoring systems have been 
developed in order to screen multiple cell lineages and to provide 
information that could be useful both for diagnosis and for 
determining disease prognosis.
IREM2
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CD56
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D
R
CD33
C
D
36
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B
C
FiGURe 3 | eight-color flow cytometric analysis of monocytic antigenic expression in a normal BM sample (left column) compared with a case of 
chronic myelomonocytic leukemia (CMML, right column). The first row shows the maturation profile of the monocytic lineage delineated by CD14 and CD300e 
(IREM-2) expression according to the Euroflow analysis strategy (19). The right plot in (A) shows monocyte maturation arrest. (B) shows the aberrant expression of 
CD56 on monocytes in a CMML patient (right) compared with normal BM (left). (C) The last row depicts the diminishing expression of CD33 on mature monocytes in 
a CMML patient (right) compared to a normal counterpart from a healthy donor (left).
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Diagnosis Utility
The first FCSS was developed by Wells and collaborators in 2003, 
and study was conducted on a cohort of 115 patients with a diag-
nosis of de novo or secondary MDS who subsequently underwent 
allogeneic hematopoietic stem cell transplantation. The immu-
nophenotypic abnormalities were categorized as normal/mild 
(0–1), moderate (2–3), or severe (≥4). The Wells FCSS correlated 
inversely with the leukocyte and absolute neutrophil counts and 
correlated directly with IPSS scores and with IPSS cytogenetic 
risk categories (29).
Comparison of high-resolution cytogenetics tests and 
the phenotypic abnormalities detected using the Wells FCSS 
showed that the immunophenotypic test was positive in 100% of 
array-positive MDS specimens and that higher flow cytometric 
abnormality scores correlated with increasing complexity of 
genomic abnormalities (30). Moreover, in patients with clonal 
abnormalities associated with MDS, the Wells FCSS had a good 
specificity [did not detect phenotypic abnormalities indicating 
myelodysplasia in 68 of 79 CGH-negative specimens (specificity 
of 86%)] and a good sensitivity [the immunophenotypic abnor-
malities suggestive of MDS were identified in 18 of 20 CGH-
positive specimens (sensitivity of 90%)] (31). Recent studies 
state that quantifying immunophenotypic aberrancies by FCSS 
is useful in MDS diagnosis, especially for identifying patients 
with a high likelihood of having MDS among patients with 
unexplained cytopenias (17, 32). However, the revised guide-
lines for the integration of flow cytometry results in the WHO 
classification of MDS, a proposal of the International/European 
LeukemiaNet (I/ELN) Working Group for Flow Cytometry 
in MDS, recommend that further studies are necessary to 
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establish whether in patients with unilineage dysplasia, normal 
karyotype, and no detected mutations, the presence of aberrant 
immunophenotypes provides added value in the diagnostic 
workup (6). The conclusion of the I/ELN Working Group was 
that no definitive diagnosis should be given if the MCF report is 
not integrated with the other diagnostic information provided 
by clinical information, blood and BM cytomorphology inter-
pretation, cytogenetics, and molecular genetics (6). This reflects 
the limited value of actual MFC assessment in MDS diagnosis.
Prognostic Utility
In 2007, a consensus was reached for cases where multiple phe-
notypic abnormalities are found in MCF. Multiple abnormalities 
should be regarded as indicative of clonal myeloid malignancy 
but do not have the prognostic value of immunophenotypic 
scores. The likelihood of a myeloid neoplasm increases with the 
number of phenotypic deviations. In the diagnostic work-up in 
suspected MDS, flow cytometry is of value in the quantitative and 
qualitative assessment of CD34+ progenitor cells (blasts), matur-
ing myeloid cells, and monocytes. The results from quantitative 
assessments may be of particular value when BM smears are 
of suboptimal quality or missing, or when monocytic cells are 
extremely immature (CMML versus AML) (33).
The recent report of the I/ELN Working Group showed that 
higher numbers of immunophenotypic aberrancies correlate 
with an increased risk of progression in MDS (6).
However, no prognostic value has been described in cases with 
low FCSS scores, such as patients with refractory cytopenia with 
unilineage dysplasia (RCUD), refractory anemia with ringed 
sideroblasts, unclassified myelodysplastic syndromes, and in 
patients with refractory cytopenia with multilineage dysplasia 
(RCMD) and low IPSS risk scores.
Recently, a prognostic score has been proposed that includes 
three parameters: sideward light scatter, CD117 expression of 
myeloid progenitor cells, and CD13 expression on monocytes. 
The MFC can refine prognostication within the IPSS-R low-risk 
category by identifying patients with worse overall survival in 
cases of high FCSS scores (34).
Treatment Response Assessment
Low FCSS scores at diagnosis and a decrease in the FCSS during 
treatment among patients classified within Int-2 and high-risk 
MDS patients identified those who are likely to respond to treat-
ment with azacitidine (35).
In addition, the aberrant phenotype of myeloblasts (e.g., in 
particular, the expression of CD7 or CD56 and loss of CD45 or 
myeloid antigens) seems to have discriminatory value because 
it identifies non-responders to growth factor therapies, such 
as erythropoiesis-stimulating agents and granulocyte colony-
stimulating factors, among low- and intermediary-risk MDS 
patients with the greatest response probability according to con-
ventional criteria (e.g., predictive model of Hellström-Lindberg 
et al.). Moreover, aberrations in myeloblasts acted as significant 
biomarkers for MDS treatment failure in multivariate analysis 
(36, 37). However, the preliminary results of this pilot study have 
to be validated in a larger cohort.
In determining the prognostic outcome in MDS patients who 
underwent allogeneic hematopoietic stem cell transplantation, 
the Wells FCSS score has proved to be useful, and the flow cyto-
metric scores correlated with post-transplantation outcome (29).
CONCLUDiNG ReMARKS
Although increasing evidence exists for the utility of MFC in the 
diagnostic evaluation of unexplained cytopenia and monocyto-
sis, the predictive value of MFC for MDS still needs improvement 
despite extensive efforts to improve the methodology.
Possible differences may be assigned to antibody clones for 
staining, antibody combinations, selection of fluorochromes, 
antibody stability, and analysis strategies.
We suggest that a rating of the different markers used in MDS 
panels must be evaluated in large multicenter studies.
In addition, the criteria for BM hemodilution evaluation need 
to be established and validated in multicenter studies in order 
to set cut-off values needed to ensure the quality of assessment.
Likewise, it may be necessary to define non-qualifying 
immunophenotypic markers that could be excluded from dif-
ferent screening scores by extrapolating to non-MDS-qualifying 
anomalies detected by karyotype test [e.g., isolated loss of the 
Y chromosome, trisomy 8 (which is frequently associated with 
aplastic anemia and a very good response to immunosuppres-
sive therapy) and del(20q), which is not associated with clear 
evidence of MDS (38)] or to other cytopenias of different origins 
(malnutrition, hematinic deficiency, multisystem organ failure, 
cytopenia after toxic injury, immune disorders, etc.). New immu-
nophenotypic footprints should be tested.
Immunophenotypic scores must also be developed to predict 
the treatment response and assess and predict the evolution of so-
called clonal cytopenias of undetermined significance (CCUS), 
which more closely resemble MDS patients than age-matched 
controls with somatic mutations (39).
In conclusion, morphology should be supplemented with 
additional new techniques for MDS diagnosis, and the utility of 
MFC has been demonstrated in the detection of early stages of 
myelodysplasia when a broad range of myeloid and non-myeloid 
antigens are evaluated. However, multicenter studies still need 
to be conducted in order to determine which markers are more 
informative in discriminating MDS from cytopenias associated 
with other non-neoplastic causes and for advancing knowledge 
about the myeloid maturation patterns. Thereafter, it will be 
necessary to construct robust and practical FCSS that can be 
implemented in routine procedures.
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